0001127602-22-026832.txt : 20221202
0001127602-22-026832.hdr.sgml : 20221202
20221202183359
ACCESSION NUMBER: 0001127602-22-026832
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221201
FILED AS OF DATE: 20221202
DATE AS OF CHANGE: 20221202
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Stonehouse Jon P
CENTRAL INDEX KEY: 0001385496
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-23186
FILM NUMBER: 221443295
MAIL ADDRESS:
STREET 1: 2190 PARKWAY LAKE DR
CITY: BIRMINGHAM
STATE: AL
ZIP: 35244
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIOCRYST PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000882796
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 621413174
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4505 EMPEROR BOULEVARD
STREET 2: SUITE 200
CITY: DURHAM
STATE: NC
ZIP: 27703
BUSINESS PHONE: 919-859-1302
MAIL ADDRESS:
STREET 1: 4505 EMPEROR BOULEVARD
STREET 2: SUITE 200
CITY: DURHAM
STATE: NC
ZIP: 27703
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2022-12-01
0000882796
BIOCRYST PHARMACEUTICALS INC
BCRX
0001385496
Stonehouse Jon P
4505 EMPEROR BLVD.
SUITE 200
DURHAM
NC
27703
1
1
President & CEO
Common Stock
2022-12-01
4
M
0
214917
1.42
A
1116747
D
Common Stock
2022-12-01
4
S
0
214917
13.00
D
901830
D
Common Stock
2022-12-02
4
M
0
82656
1.42
A
984486
D
Common Stock
2022-12-02
4
S
0
82656
12.80
D
901830
D
Common Stock
5000
I
By wife as co-trustee of the Caroline Stonehouse Irrevocable Trust
Common Stock
5000
I
By wife as co-trustee of the Samuel Stonehouse Irrevocable Trust
Emp. Stock Option (Right to Buy)
1.42
2022-12-01
4
M
0
214917
0
D
2014-01-01
2023-01-01
Common Stock
214917
82656
D
Emp. Stock Option (Right to Buy)
1.42
2022-12-02
4
M
0
82656
0
D
2014-01-01
2023-01-01
Common Stock
82656
0
D
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. The options were originally granted to the reporting person on January 1, 2013 and would have expired on January 1, 2023. The shares sold subsequent to the exercise of such options represent less than 10% of the reporting person's holdings of the issuer's securities.
The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $12.75 to $13.45. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $12.69 to $12.92. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
/s/ Alane P. Barnes, by power of attorney
2022-12-02